Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 0.66 MYR
Change Today -0.005 / -0.75%
Volume 1.0M
TMCL On Other Exchanges
Symbol
Exchange
Kuala Lumpur
As of 4:53 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

tmc life sciences bhd (TMCL) Snapshot

Open
0.66
Previous Close
0.67
Day High
0.67
Day Low
0.66
52 Week High
02/9/15 - 0.75
52 Week Low
05/21/14 - 0.39
Market Cap
791.7M
Average Volume 10 Days
2.6M
EPS TTM
0.01
Shares Outstanding
1.2B
EX-Date
10/24/14
P/E TM
66.0x
Dividend
0.0030
Dividend Yield
0.45%
Current Stock Chart for TMC LIFE SCIENCES BHD (TMCL)

Related News

No related news articles were found.

tmc life sciences bhd (TMCL) Related Businessweek News

No Related Businessweek News Found

tmc life sciences bhd (TMCL) Details

TMC Life Sciences Berhad, an investment holding company, primarily operates a multi-disciplinary tertiary care center and fertility center in Malaysia. The company’s tertiary care center provides healthcare services in various medical/surgical specialties and subspecialties, including anaesthesiology, obstetrics and gynaecology, ophthalmology, cardiology, dermatology, endocrinology, gastroenterology, fertility, hepatology, internal medicine, nephrology, paediatrics, psychiatry, radiology and interventional radiology, respiratory medicine, and urology, as well as breast and endocrine, cancer, cardiothoracic, colorectal, ENT, head and neck laser, general and minimally invasive, hepatobiliary, neuro, hand and micro, bariatric, oral and maxillofacial, orthopaedic, plastic and reconstructive, vascular and endovascular, and upper gastrointestinal surgeries. Its fertility center provides a range of fertility treatments for couples. The company also operates a women’s clinic; provides consultancy, laboratory, and embryology services; and offers gynaecological and fertility problem management services. In addition, it is involved in developing, marketing, and managing healthcare programs; and marketing and promoting healthcare products; and research and development, and property investment activities. TMC Life Sciences Berhad was founded in 1994 and is headquartered in Petaling Jaya, Malaysia. TMC Life Sciences Berhad operates as a subsidiary of Sasteria Pte. Ltd.

Founded in 1994

tmc life sciences bhd (TMCL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tmc life sciences bhd (TMCL) Key Developments

TMC Life Sciences Berhad Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended February 28, 2015

TMC Life Sciences Berhad announced unaudited consolidated earnings results for the third quarter and nine months ended February 28, 2015. For the quarter, the company reported revenue of MYR 26,411,000 against MYR 21,715,000 a year ago. Profit from operations was MYR 3,848,000 against MYR 3,527,000 a year ago. Profit before taxation was MYR 3,196,000 against MYR 1,740,000 a year ago. Profit after taxation was MYR 2,906,000 against MYR 1,743,000 a year ago. Profit attributable to owners of the parent was MYR 2,906,000 or MYR 0.32 per basic and diluted share against MYR 1,743,000 or MYR 0.14 per diluted share a year ago. Revenue increased by 22% compared to the previous corresponding quarter. Higher revenue was contributed by higher patient load catered for by expanded bed capacity and additional consultants recruited. Despite the increase in operating expenditure especially on corporate exercise expenses and staff cost, higher profit before taxation was achieved in the current quarter mainly due to higher revenue and interest income. For the nine months, the company reported revenue of MYR 74,684,000 against MYR 62,742,000 a year ago. Profit from operations was MYR 10,132,000 against MYR 9,351,000 a year ago. Profit before taxation was MYR 5,961,000 against MYR 3,937,000 a year ago. Profit after taxation was MYR 5,941,000 against MYR 3,776,000 a year ago. Profit attributable to owners of the parent was MYR 5,941,000 or MYR 0.65 per basic and diluted share against MYR 3,776,000 or MYR 0.31 per diluted share a year ago. Net cash flows from operating activities were MYR 12,190,000 against MYR 7,984,000 a year ago. Acquisition of property plant and equipment was MYR 13,027,000 against MYR 2,793,000 a year ago. The group recorded 19% growth in revenue for the 9 months ended 28 February 2015 compared with the corresponding period in the previous financial year. The growth was contributed by additional bed capacity and more variety of services offered coupled with continuing marketing activities. The group recorded profit before taxation was mainly due to higher revenue and interest income.

TMC Life Sciences Berhad Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended November 30, 2014

TMC Life Sciences Berhad reported unaudited consolidated earnings results for the second quarter and six months ended November 30, 2014. For the quarter, the company reported revenue of MYR 25.101 million against MYR 22.220 million a year ago. Profit from operations was MYR 3.895 million against MYR 4.322 million a year ago. Profit before taxation was MYR 2.121 million against MYR 2.513 million a year ago. Profit attributable to owners of the parent was MYR 2.307 million or 0.20 sen per diluted share against MYR 2.401 million or 0.20 sen per diluted share a year ago. Higher revenue was contributed by higher patient load catered for by increased bed capacity and additional consultants recruited. Increased operating expenditure especially on staff cost had resulted in lower profit before taxation for the current quarter. For the six months, the company reported revenue of MYR 48.273 million against MYR 41.027 million a year ago. Profit from operations was MYR 6.284 million against MYR 5.824 million a year ago. Profit before taxation was MYR 2.765 million against MYR 2.197 million a year ago. Profit attributable to owners of the parent was MYR 3.035 million or 0.26 sen per diluted share against MYR 2.033 million or 0.17 sen per diluted share a year ago. Net cash flows from operating activities were MYR 8.902 million against MYR 7.382 million a year ago. Acquisition of property, plant and equipment was MYR 5.873 million against MYR 1.933 million a year ago. The growth in revenue was contributed by additional bed capacity and more variety of services offered coupled with continuing marketing activities.

TMC Life Sciences Berhad to Expand Hospital Facilities

TMC Life Sciences Berhad will expand the facilities at its hospital, Tropicana Medical Centre, with the first phase costing between MYR 250 million and MYR 300 million. The first-phase expansion included the construction of a new building to house another 180 in-patient beds, 11,891 sq metre of specialist outpatient clinics, five extra operating theatres and 15,793 sq metre of commercial/retail space.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMCL:MK 0.66 MYR -0.005

TMCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TMCL.
View Industry Companies
 

Industry Analysis

TMCL

Industry Average

Valuation TMCL Industry Range
Price/Earnings 76.7x
Price/Sales 6.2x
Price/Book 2.1x
Price/Cash Flow 91.7x
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TMC LIFE SCIENCES BHD, please visit www.tmclife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.